Skip to main content
Clinical Trials/NCT04176926
NCT04176926CompletedNot Applicable

Validation of Software for Assessment of Atrial Fibrillation From Data Acquired by a Wearable Smartwatch

Fitbit LLC10 sites in 2 countries472 target enrollmentStarted: October 29, 2019Last updated:
Conditions

Trial Snapshot

Phase
Not Applicable
Status
Completed
Sponsor
Fitbit LLC
Enrollment
472
Locations
10
Primary Endpoint
Evaluate the software algorithm's ability to classify a heart rhythm as sinus rhythm or atrial fibrillation from a waveform equivalent to a Lead I ECG.

Study Overview

Brief Summary

The goal of this study is to validate the Fitbit ECG software algorithm's ability to detect atrial fibrillation using data derived from a Fitbit wrist-worn consumer device that features a single lead ECG. The performance of the software application will be measured against centralized Core Lab physician-adjudicated 12-lead ECG tracings from FDA cleared ECG monitors as reference standards. The Fitbit software is intended as a pre-screening technology. It should identify candidates who may benefit from further evaluation. The software is not intended to be a diagnostic system.

Study Design

Study Type
Observational
Observational Model
Case Control
Time Perspective
Prospective

Eligibility Criteria

Ages
22 Years to — (Adult, Older Adult)
Sex
All
Accepts Healthy Volunteers
Yes

Inclusion Criteria

  • Women and men 22 years of age or older
  • Capable of giving informed consent
  • Sufficient manual dexterity to capture an ECG from the Fitbit wrist-worn device.
  • Subjects in the atrial fibrillation (AF) cohort must have a known history of AF and must be in -AF at the time of enrollment based on the screening ECG

Exclusion Criteria

  • Anti-arrhythmic (rhythm control) medication use (such as amiodarone or flecainide)
  • Cardiac pacemaker or implantable cardioverter-defibrillator
  • History of a life-threatening rhythm such as ventricular tachycardia or ventricular fibrillation
  • Subjects in the sinus rhythm (SR) cohort should not have any history of atrial fibrillation and should not be in atrial fibrillation or other atrial arrhythmia at the time of enrollment based on the screening ECG

Outcomes

Primary Outcomes

Evaluate the software algorithm's ability to classify a heart rhythm as sinus rhythm or atrial fibrillation from a waveform equivalent to a Lead I ECG.

Time Frame: Through study completion, an average of 4 months

Sensitivity and specificity of the software algorithm in classifying sinus rhythm and atrial fibrillation from the equivalent of a Lead I ECG waveform, compared with physician's interpretation of a standard 12-lead ECG. Performance goals are 90% (sensitivity) and 92% (specificity)

Secondary Outcomes

  • Confirm the software's ability to produce a waveform clinically equivalent to a Lead I ECG from a clinical reference device (12-lead ECG).(Through study completion, an average of 4 months)

Investigators

Sponsor
Fitbit LLC
Sponsor Class
Industry
Responsible Party
Sponsor

Study Sites (10)

Loading locations...

Similar Trials